Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-09-20

Clinical Trial Update: Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Pyronaridine Artesunate (3:1) to Coartem in Plasmodium falciparum malaria; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Coartem (artemether-lumefantrine)
  • Pyronaridine Artesunate (3:1) (pyronaridine artesunate)

Snippet

Sponsor: Medicines for Malaria Venture | Conditions: Malaria | Phase 3 | Status: COMPLETED | Results posted: 2021-09-20